F8 and hemorrhagic disease: In the case of Hemophilia A (HA), a bleeding disorder, about one third of the severe HA patients receiving replacement therapy using recombinant Factor VIII (FVIII) develop neutralizing anti-FVIII antibodies, referred to as inhibitors, that abrogate the biological activity and hemostatic efficacy of the administered FVIII7–9.